Last reviewed · How we verify
SCTA01
At a glance
| Generic name | SCTA01 |
|---|---|
| Also known as | Recombinant anti-SARS-CoV-2 spike protein monoclonal antibody |
| Sponsor | Sinocelltech Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19 (PHASE2, PHASE3)
- A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19 (PHASE1, PHASE2)
- To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19 (PHASE2, PHASE3)
- Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects (PHASE1)
- The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCTA01 CI brief — competitive landscape report
- SCTA01 updates RSS · CI watch RSS
- Sinocelltech Ltd. portfolio CI